Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response

Eric W Chak, Sammy Saab

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic blood borne infection in the United States. Since the advent of blood screening protocols in the early 1990s, injection drug use has become the leading cause of infection. Hepatitis C can have both hepatic and nonhepatic manifestations of infection. Hepatic manifestations include hepatic fibrosis, cirrhosis, liver cancer, and liver failure. The standard treatment for chronic HCV is combination therapy with pegylated interferon-α and ribavirin. Although pegylated interferon and ribavirin has been used against HCV for close to a decade, advances in therapy have centered on doses and treatment durations. There has been increasing interest in applying on-treatment response or viral kinetics to predict antiviral response rates and shape therapeutic intervention. Protease inhibitors are a promising adjuvant to combination therapy, but their efficacy and safety are still under investigation.

Original languageEnglish (US)
Pages (from-to)147-154
Number of pages8
JournalCurrent Hepatitis Reports
Volume9
Issue number3
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Ribavirin
Interferons
Hepacivirus
Liver Neoplasms
Therapeutics
Infection
Liver
Liver Failure
Chronic Hepatitis C
Hepatitis C
Sustained Virologic Response
Protease Inhibitors
Liver Cirrhosis
Antiviral Agents
Fibrosis
Safety
Injections
Pharmaceutical Preparations

Keywords

  • Chronic hepatitis C
  • Hepatitis C virus
  • Pegylated interferon-α
  • Protease inhibitors
  • Ribavirin
  • Viral kinetics

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response. / Chak, Eric W; Saab, Sammy.

In: Current Hepatitis Reports, Vol. 9, No. 3, 08.2010, p. 147-154.

Research output: Contribution to journalReview article

@article{9d1c66c4d0a2463db825ead9f7aae6a0,
title = "Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response",
abstract = "Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic blood borne infection in the United States. Since the advent of blood screening protocols in the early 1990s, injection drug use has become the leading cause of infection. Hepatitis C can have both hepatic and nonhepatic manifestations of infection. Hepatic manifestations include hepatic fibrosis, cirrhosis, liver cancer, and liver failure. The standard treatment for chronic HCV is combination therapy with pegylated interferon-α and ribavirin. Although pegylated interferon and ribavirin has been used against HCV for close to a decade, advances in therapy have centered on doses and treatment durations. There has been increasing interest in applying on-treatment response or viral kinetics to predict antiviral response rates and shape therapeutic intervention. Protease inhibitors are a promising adjuvant to combination therapy, but their efficacy and safety are still under investigation.",
keywords = "Chronic hepatitis C, Hepatitis C virus, Pegylated interferon-α, Protease inhibitors, Ribavirin, Viral kinetics",
author = "Chak, {Eric W} and Sammy Saab",
year = "2010",
month = "8",
doi = "10.1007/s11901-010-0047-1",
language = "English (US)",
volume = "9",
pages = "147--154",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response

AU - Chak, Eric W

AU - Saab, Sammy

PY - 2010/8

Y1 - 2010/8

N2 - Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic blood borne infection in the United States. Since the advent of blood screening protocols in the early 1990s, injection drug use has become the leading cause of infection. Hepatitis C can have both hepatic and nonhepatic manifestations of infection. Hepatic manifestations include hepatic fibrosis, cirrhosis, liver cancer, and liver failure. The standard treatment for chronic HCV is combination therapy with pegylated interferon-α and ribavirin. Although pegylated interferon and ribavirin has been used against HCV for close to a decade, advances in therapy have centered on doses and treatment durations. There has been increasing interest in applying on-treatment response or viral kinetics to predict antiviral response rates and shape therapeutic intervention. Protease inhibitors are a promising adjuvant to combination therapy, but their efficacy and safety are still under investigation.

AB - Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic blood borne infection in the United States. Since the advent of blood screening protocols in the early 1990s, injection drug use has become the leading cause of infection. Hepatitis C can have both hepatic and nonhepatic manifestations of infection. Hepatic manifestations include hepatic fibrosis, cirrhosis, liver cancer, and liver failure. The standard treatment for chronic HCV is combination therapy with pegylated interferon-α and ribavirin. Although pegylated interferon and ribavirin has been used against HCV for close to a decade, advances in therapy have centered on doses and treatment durations. There has been increasing interest in applying on-treatment response or viral kinetics to predict antiviral response rates and shape therapeutic intervention. Protease inhibitors are a promising adjuvant to combination therapy, but their efficacy and safety are still under investigation.

KW - Chronic hepatitis C

KW - Hepatitis C virus

KW - Pegylated interferon-α

KW - Protease inhibitors

KW - Ribavirin

KW - Viral kinetics

UR - http://www.scopus.com/inward/record.url?scp=77955984219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955984219&partnerID=8YFLogxK

U2 - 10.1007/s11901-010-0047-1

DO - 10.1007/s11901-010-0047-1

M3 - Review article

AN - SCOPUS:77955984219

VL - 9

SP - 147

EP - 154

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 3

ER -